TxCell launches new manufacturing process development laboratories and technology transfer academy
French firm aims to increase automation and make economic efficiencies
French biotechnology firm TxCell, a developer of personalised cellular immunotherapies using regulatory T-cells to treat severe chronic inflammatory and autoimmune diseases, has opened its new process industrialisation laboratories and technology transfer academy facilities in the premises of GenBiotech in Sophia Antipolis, France.
These new facilities will be primarily dedicated to improving the existing TxCell manufacturing process for its ASTrIA (Antigen Specific Treg for Inflammation and Autoimmunity) platform as well as to the development of a manufacturing process for the firm's new ENTrIA (Engineered Treg for Inflammation and Autoimmunity) technology.
The firm expects the outcome will be an increase in automation and economic efficiencies as well as a shortening of the manufacturing process of all TxCell products across all of its platforms.
'TxCell is the only clinical stage cellular therapy company dedicated to the science of regulatory T lymphocytes (Tregs). As a result, TxCell is integrating its own research with recent technological advancements across a variety of fields to make the manufacturing process of our product portfolio as economic as possible,' said Miguel Forte, COO of TxCell.
The new facilities will accelerate the development of the commercial manufacturing process for products that result from the TxCell ASTrIA platform
'The new TxCell facilities will be dedicated to accelerating the development of the commercial manufacturing process for products that result from the TxCell ASTrIA platform. In addition, it will allow the development of a new manufacturing process for products derived from the new TxCell ENTrIA platform.'
The facilities will also host the TxCell Academy for Technology Transfer, which will be responsible for educating and training all contract manufacturing partners (CMOs, including MaSTherCell).
In addition, the academy will be used to train future strategic partners (licensed and/or co-developing pharmaceutical companies) on the manufacturing processes of TxCell’s personalised cellular therapies. This will have the aim of facilitating and accelerating all transfer of TxCell technologies to third parties.
'The opening of the new process development and technology transfer laboratories in the facilities of GenBiotech is a great development for TxCell,' added Stéphane Boissel, CEO of TxCell.
'A significant part of TxCell’s strategic focus for the next three years will include improving the manufacturing process for the current group of products from the TxCell ASTrIA platform as well as developing a process for products from the new TxCell ENTrIA platform. In addition, in the context of a rapidly developing market for cellular therapy technologies, educating our manufacturing partners and future strategic partners about these processes will be crucial for TxCell.'
